Refine
Has Fulltext
- no (8)
Document Type
- Article (8) (remove)
Is part of the Bibliography
- yes (8)
Keywords
- Cost-effectiveness (3)
- depression (2)
- BDNF (1)
- Brain-derived neurotrophic factor (BDNF) (1)
- Cardiovascular disease (1)
- Cardiovascular magnetic resonance (1)
- Coronary angiography (1)
- Coronary artery disease (1)
- Coronary heart disease (CHD) (1)
- Depression (1)
- Drug-coated balloon (1)
- Drug-eluting stent (1)
- Prevention (1)
- Renal sympathetic denervation (1)
- Resistant hypertension (1)
- Restenosis (1)
- Revascularization (1)
- Scintigraphy (1)
- Serum (1)
- acute coronary syndrome (1)
- cardiovascular diseases (1)
- coronary artery disease (1)
- coronary heart disease (1)
- cost and cost analysis (1)
- cost-benefit analysis (1)
- diagnosis (1)
- drug monitoring (1)
- heart failure (1)
- hypertension (1)
- medication adherence (1)
- probability (1)
- risk assessment (1)
- screening (1)
- somatic comorbidity (1)
- validity (1)
Institute
Objective:
Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF).
Methods:
The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment.
Results:
Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS.
Conclusion:
Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.